On April 23, Amarin Corp. issued a press release announcing that the U.S. FDA has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG =200 mg/dL and < 500 mg/dL) with mixed dyslipidemia.
The FDA's review of Vascepa is expected to be completed by December 20, 2013.
The USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co., recently was honored with finalist designation for two major industry awards, the PRSA National Silver Anvil and the PRSA Big Apple Awards.
Please help us gain insight into the use of plaque information obtained from coronary CTA in managing your patients by participating in “Potential Clinical Applications of Plaque Imaging by CTA: A Survey,” conducted by Harvey Hecht and Jagat Narula from Mount Sinai Medical Center and Stephan Achenbach from The University of Erlangen.
The answer sheet to the survey is available at the end of the document.
.jpg)
.png)
